Thalidomide for refractory gastrointestinal bleeding from vascular malformations in patients with significant comorbidities

Table 2 Patient characteristics

Patient	Age	Sex	Comorbidities	Cause of GIB	Prior failed treatments	Iron supplementation	Comments
1	58	M	LVAD	GIAD	Octreotide
2	67	F	ESRD	GIAD		Sodium ferric gluconate	Aspirin
3	70	M	LVAD	GIAD	Octreotide	Ferrous sulfate	Warfarin
4	61	F	Cirrhosis	GIAD		Ferrous sulfate
5	81	M	LVAD	GIAD	Octreotide	Ferrous sulfate	Aspirin, warfarin
6	83	M	CAD, AS, AAA, CVA	GIAD	Octreotide, estrogen	Polysaccharide iron	Aspirin, cilostazol, plavix
7	72	M	Hepatoportal sclerosis	GAVE
8	69	F	Polyclonal gammopathy	GIAD
9	70	F	ESRD, HHT	GIAD	Octreotide	Ferrous sulfate
10	62	M	Cirrhosis	GAVE		Ferrous fumarate
11	58	M	Cirrhosis, CHF, ESRD	GAVE	Octreotide	Ferrous sulfate
12	64	F	Cirrhosis, MDS, NHL	GAVE
13	80	F	AS	GIAD
14	74	M	NSCLC, AFIB, MDS	GIAD			Lost to follow-up
15	68	M	AFIB, CHF, Cirrhosis	GAVE			Aspirin, warfarin, lost to follow-up

LVAD: Left ventricular assist device; ESRD: End stage renal disease; CAD: Coronary artery disease; AS: Aortic stenosis; AAA: Abdominal aortic aneurysm; CVA: Cerebrovascular accident; HHT: Hereditary hemorrhagic telangiectasia; CHF: Congestive heart failure; MDS: Myelodysplastic syndrome; NHL: Non-Hodgkin lymphoma; NSCLC: Non-small cell lung cancer; AFIB: Atrial fibrillation; GIAD: Gastrointestinal angiodysplasia; GAVE: Gastric antral vascular ectasia.